In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 2, 2004, Pages 247-251

  Athamna, A ^a   Massalha, M ^a   Athamna, M ^a,b   Nura, A ^a   Medlej, B ^a   Ofek, I ^b   Bast, D ^c   Rubinstein, E ^b,d  

^a Triangle Research/Development Center   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MOUNT SINAI HOSPITAL   (Canada)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

lactams; Anthrax; Fluoroquinolones; Macrolides

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; KETOLIDE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELITHROMYCIN; TETRACYCLINE; VANCOMYCIN;

ANTHRAX; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DILUTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE; TIME;

ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; DRUG RESISTANCE; MICROBIAL SENSITIVITY TESTS; TIME FACTORS;

EID: 1242330019     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh016     Document Type: Article

References (18)

1. Friedlander, A. M., Welkos, S. L., Pitt, M. L. M. et al. (1993). Post-exposure prophylaxis against experimental inhalation anthrax. Journal of Infectious Diseases 167, 1239-42.
2. Jernigan, D. B., Raghunathan, P. L., Bell, B. P. et al. (2002). Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerging Infectious Diseases 8, 1019-28.
3. Drago, L., De Vecchi, E., Lombardi, A. et al. (2002). Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates. Journal of Antimicrobial Chemotherapy 50, 1059-63.
4. Mandell, L., Ball, P. & Tillotson, G. (2001). Antimicrobial safety and tolerability: differences and dilemmas. Clinical Infectious Diseases 32, Suppl. 1, S72-9.
5. Worlitzsch, D., Kaygin, H., Steinhuber, A. et al. (2001) Effects of amoxicillin, gentamicin and moxifloxacin on the hemolytic activity of Staphylococcus aureus in vitro and in vivo. Antimicrobial Agents and Chemotherapy 45, 196-202.
6. Mohammed, M. J., Marston, C. K., Popovic, T. et al. (2002). Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. Journal of Clinical Microbiology 40, 1902-7.
7. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Wayne, PA, USA.
8. Brook, I., Elliott, T. B., Pryor, H. I., II et al. (2001). In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. International Journal of Antimicrobial Agents 18, 559-62.
9. Coker, P. M., Smith, K. L. & Hugh-Jones, M. E. (2002). Antimicrobial susceptibility of diverse Bacillus anthracis isolates. Antimicrobial Agents and Chemotherapy 46, 3843-5.
10. Bryskier, A. (2002). Bacillius anthracis and antibacterial agents. Clinical Microbiology and Infectious Diseases 8, 467-78.
11. Heine, H. S., Dicks, R. & Byrne, W. R. (2000). In vitro activity of daptomycin, sparfloxacin, quinupristin-dalfopristin and other antibiotics against Bacillus anthracis strains. In Program and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 2000. Abstract 517, p. 167. American Society for Microbiology, Washington, DC, USA.
12. Dogany, M. & Aydin, N. (1991). Antimicrobial susceptibility of Bacillus anthracis. Scandinavian Journal of Infectious Diseases 23, 332-5.
13. Lightfoot, N. F., Scott, R. J. D. & Turnbull, P. C. B. (1990). Antimicrobial susceptibility of Bacillus anthracis. Salisbury Medical Bulletin 68, Suppl., 95-8.
14. Lewin, C. S., Morrissey, I. & Smith, J. T. (1991). The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment. European Journal of Clinical Microbiology & Infectious Diseases 10, 240-8.
15. Lister, P. D. (2001). Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clinical Infectious Diseases 32, Suppl. 1, S33-8.
16. Dalhoff, A. (2001). Comparative in vitro and in vivo activity of the C-8 mythoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clinical Infectious Diseases 32, Suppl. 1, S16-22.
17. Grimwood, K., To, M., Rabin, H. R. et al. (1989) Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations. Antimicrobial Agents and Chemotherapy 33, 41-7.
18. Morrison, D. C. & Bucklin, S. E. (1996). Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis. Scandinavian Journal of Infectious Diseases Supplementum 101, 3-8.